PD-L1 expression by IHC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-PDL1-EXPRESSION |
|---|---|
| Type | Biomarker |
| Aliases | B7-H1CD274PD-L1PD-L1 expressionЕкспресія PD-L1 (ІГХ) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC on FFPE biopsy (22C3, SP142, SP263 clones — assay-specific scoring) UnitsTumor Proportion Score (TPS) % OR Combined Positive Score (CPS) |
| Related biomarkers | None declared |
Notes
Cross-disease relevance — checkpoint inhibitor response marker: - **Classical Hodgkin Lymphoma**: 9p24 amplification → universal PD-L1 over-expression → dramatic response to nivolumab / pembrolizumab (~70% ORR in r/r). Approved for r/r cHL after autoSCT + brentuximab failure. - **Primary Mediastinal Large B-Cell Lymphoma (PMBCL)**: similar 9p24 + universal PD-L1 → checkpoint-responsive. Pembrolizumab approved r/r PMBCL. - **EBV+ neoplasms** (EBV+ DLBCL elderly, NK/T, PTLD): variable PD-L1 + checkpoint-response in subset. - **Mediastinal Gray Zone Lymphoma**: PD-L1+ subset. - Most other DLBCL / NHL: PD-L1 expression variable, response rates lower; not standard. Algorithm impact: future 2L+ pembrolizumab/nivolumab routing for cHL r/r post-autoSCT. PMBCL future scope (Tier 2 disease).
Used By
Biomarker
BIO-PDL1-22C3-CLONE- PD-L1 IHC — Dako 22C3 pharmDx cloneBIO-PDL1-28-8-CLONE- PD-L1 IHC — Dako 28-8 pharmDx cloneBIO-PDL1-CPS- PD-L1 Combined Positive Score (CPS)BIO-PDL1-SP142-CLONE- PD-L1 IHC — Ventana SP142 cloneBIO-PDL1-SP263-CLONE- PD-L1 IHC — Ventana SP263 clone
Red flag
RF-BREAST-HIGH-RISK-BIOLOGY- Germline or somatic BRCA1/2 mutation, PIK3CA mutation, ESR1 mutation, HER2-amplification,...